---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-009225"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-04-06T23:59:59+00:00"
generated_at: "2026-06-26T09:16:15.858724+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncotelic forms joint venture with Dragon Overseas; Dragon to invest $27.6M for 55% stake

## Summary
- Dragon Overseas invests $27.6M in cash and assets for 55% of JV; Oncotelic contributes OT-101 licenses for 45%.
- Oncotelic eligible for up to $50M from sale of RPD Priority Review Voucher for OT-101 (DIPG) after marketing approval.
- JV to develop TGF-β therapeutics, initially focusing on OT-101 for DIPG, pancreatic cancer, and glioblastoma.
- If Series A of ≥$20M not completed by Aug 31, 2022, Dragon's funding drops to $250K/month; licenses revert on termination.

## SEC filing metadata
- accession: 0001493152-22-009225
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222009225/0001493152-22-009225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222009225/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-009225
- JSON: https://secwatch.observer/filing/0001493152-22-009225.json
- Plain text: https://secwatch.observer/filing/0001493152-22-009225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.